Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2013

Date: July 31, 2013
Pages: 48
Price:
US$ 2,000.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: F6A4A848946EN
Leaflet:

Download PDF Leaflet

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2013
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia). Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • A snapshot of the global therapeutic scenario for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).
  • A review of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.
Reasons to buy
  • Identify and understand important and diverse types of therapeutics under development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia).
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Overview
Therapeutics Development
An Overview of Pipeline Products for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia)
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics under Development by Companies
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Products under Development by Companies
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics Development
Amgen Inc.
Merck & Co., Inc.
ReGenX Biosciences, LLC
Cerenis Therapeutics SA
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
anacetrapib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CER-001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
evolocumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug For Familial Hypercholesterolemia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antisense Oilgonucleotides - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Drug Profile Updates
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Discontinued Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics - Dormant Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Product Development Milestones
Featured News & Press Releases
Dec 13, 2012: CHMP Turns Down Genzyme's Kynamro For Treatment Of Patients With Certain Forms Of Familial Hypercholesterolaemia
Nov 05, 2012: Amgen's AMG 145 Combination Therapy Significantly Reduced LDL Cholesterol In Patients With Heterozygous Familial Hypercholesterolemia
Jul 20, 2012: Sanofi And Regeneron Pharma Launch Comprehensive Phase III Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
May 26, 2012: Sanofi And Regeneron Pharma Announce Publication Of Positive Phase II Results Of Lipid-Lowering PCSK9 Antibody In The Lancet
Apr 30, 2012: Aegerion Announces FDA Acceptance Of Lomitapide's New Drug Application For Review
Apr 27, 2012: Merck Wins US Zetia/Vytorin Patent Infringement Lawsuit
Apr 10, 2012: Regenx Receives FDA Orphan Designation For Treatment Of Familial Hypercholesterolemia Using NAV rAAV8 Vectors
Mar 29, 2012: Genzyme And Isis Announce Submission Of NDA For KYNAMRO In Homozygous Familial Hypercholesterolemia
Mar 25, 2012: Amgen's PCSK9 Inhibitor Reduces LDL Cholesterol Up to 81% In Phase Ib Study
Mar 20, 2012: Aegerion Announces EMA Acceptance For Review Of Marketing Authorization Application For Lomitapide
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products Under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H2 2013
Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Late Stage Development, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Amgen Inc., H2 2013
Merck & Co., Inc., H2 2013
ReGenX Biosciences, LLC, H2 2013
Cerenis Therapeutics SA, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Drug Profile Updates
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Discontinued Products
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) Therapeutics – Dormant Products

LIST OF FIGURES

Number of Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia), H2 2013
Products under Development for Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) – Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Late Stage Products, H2 2013
Mid Clinical Stage Products, H2 2013
Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Hypercholesterolemia - Pipeline Review, Q4 2010 US$ 500.00 Dec, 2010 · 60 pages
Hypercholesterolemia - Pipeline Review, Q1 2011 US$ 500.00 Mar, 2011 · 58 pages
Hypercholesterolemia - Pipeline Review, H2 2013 US$ 2,000.00 Sep, 2013 · 120 pages

Ask Your Question

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Pipeline Review, H2 2013
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry: